## 506620927 04/21/2021

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6667734

| SUBMISSION TYPE:      | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT     |

### **CONVEYING PARTY DATA**

| Name                           | Execution Date |
|--------------------------------|----------------|
| ASTRAZENECA PHARMACEUTICALS LP | 10/09/2019     |

### **RECEIVING PARTY DATA**

| Name:             | ASTRAZENECA UK LIMITED      |  |
|-------------------|-----------------------------|--|
| Street Address:   | 1 FRANCIS CRICK AVENUE      |  |
| Internal Address: | CAMBRIDGE BIOMEDICAL CAMPUS |  |
| City:             | CAMBRIDGE                   |  |
| State/Country:    | ENGLAND                     |  |
| Postal Code:      | CB2 0AA                     |  |

### **PROPERTY NUMBERS Total: 1**

| Property Type       | Number   |
|---------------------|----------|
| Application Number: | 16657375 |

#### **CORRESPONDENCE DATA**

**Fax Number:** (301)398-9306

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 301-398-0000

Email: patents@astrazeneca.com

Correspondent Name: ASTRAZENECA MEDIMMUNE

Address Line 1: ONE MEDIMMUNE WAY

Address Line 4: GAITHERSBURG, MARYLAND 20878

| ATTORNEY DOCKET NUMBER: | B7H1-510-US-NP2_ASSIGN7 |  |
|-------------------------|-------------------------|--|
| NAME OF SUBMITTER:      | MARA LOUEY              |  |
| SIGNATURE:              | /MARA LOUEY/            |  |
| DATE SIGNED:            | 04/21/2021              |  |

### **Total Attachments: 2**

source=2021-04-21 - B7H1-510-US-NP2 - Assignment 7 - AZPLP\_to\_AZUK#page1.tif source=2021-04-21 - B7H1-510-US-NP2 - Assignment 7 - AZPLP\_to\_AZUK#page2.tif

PATENT 506620927 REEL: 055987 FRAME: 0351

#### ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the October 18, 2018 and May 30, 2019 (the "Effective Date") by and between

- (1) ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America ("Assignor"); and
- (2) ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under No. 3674842 with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, England CB2 0AA ("Assignee").

WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to: US Provisional Application No. 62/747,420 filed on October 18, 2018 and US Provisional Application No. 62/854,566 filed on May 30, 2019 (the "Application") and in and to the inventions and improvements disclosed in such Application.

# NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

- 1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
- 2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
- 3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
  - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
  - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
  - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, reexaminations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
- 4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

PATENT REEL: 055987 FRAME: 0352 5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed for and on behalf of

ASTRÀZENECA PHÀRMACEUTICALS LP

Name: Meaghan Lynn Richmond Title: Authorised Signatory

Date: 09-04-7019

PATENT REEL: 055987 FRAME: 0353

RECORDED: 04/21/2021